Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC000937 | Panoply™ Human ARL6IP1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC000937 | Panoply™ Human ARL6IP1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2886 | Human ARL6IP1 KO Cell Line-HEK293T | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD01339Z | Human ARL6IP1 adenoviral particles | Inquiry |
| LV05466L | human ARL6IP1 (NM_015161) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHG072901 | shRNA set against Rat Arl6ip1(NM_198737.2) | Inquiry |
| SHG072919 | shRNA set against Human ARL6IP1(NM_015161.1) | Inquiry |
| SHH240286 | shRNA set against Human ARL6IP1 (NM_015161.1) | Inquiry |
| SHH240290 | shRNA set against Mouse ARL6IP1 (NM_019419.2) | Inquiry |
| SHH240294 | shRNA set against Rat ARL6IP1 (NM_198737.2) | Inquiry |
| SHW000263 | shRNA set against Chicken ARL6IP1 (NM_001006171) | Inquiry |
| SHW017220 | shRNA set against Danio rerio ARL6IP1 (NM_201112) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR298483 | Human ARL6IP1 ORF Clone(NM_015161.1) | Inquiry |
| CDFH001172 | Human ARL6IP1 cDNA Clone(NM_015161.1) | Inquiry |
| CDFR015141 | Rat Arl6ip1 cDNA Clone(NM_198737.2) | Inquiry |
| MiUTR1H-00572 | ARL6IP1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-00377 | ARL6IP1 miRNA 3'UTR clone | Inquiry |
| SKO0312 | ARL6IP1 Validated sgRNA vector | Inquiry |
| CDCB158537 | Human ARL6IP1 ORF clone (BC010281) | Inquiry |
| CDCB161738 | Chicken ARL6IP1 ORF Clone (NM_001006171) | Inquiry |
| CDCB178695 | Danio rerio ARL6IP1 ORF Clone (NM_201112) | Inquiry |
| CDCB184824 | Rabbit ARL6IP1 ORF clone (XM_008257785.1) | Inquiry |
| CDCH017518 | Mouse ARL6IP1 ORF clone(NM_019419.2) | Inquiry |
| CDCR382192 | Rat Arl6ip1 ORF Clone(NM_198737.2) | Inquiry |
| CDCS413888 | Human ARL6IP1 ORF Clone (BC010281) | Inquiry |